Novo Nordisk leaps on new obesity drug data
Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 diabetes and Wegovy for obesity but is coming under competitive pressure from rival therapies from Eli Lilly based on dual GIP/GLP-1 agonist tirzepatide.
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...
The hugely popular medications Ozempic and Wegovy​, used for diabetes and weight loss, will be included in the next round of ...
In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...
Newsable Asianet News on MSN9h
Novo Nordisk Stock Eyes Best Day In 17 Months On New Obesity Drug Trial Data: Retail Breathes EasyShares of Novo Nordisk surged over 13% in premarket trading Friday, driven by promising topline results from a early-stage ...
GLP-1 weight loss drugs, Ozempic and Wegovy, will be targeted in the next round of Medicare price negotiations in 2027, along ...
The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare ...
IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 ...
Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback